A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress) Meeting Abstract
| Authors: | Alencar, A. J.; Roeker, L. E.; Hoffman, M.; Murthy, G. S. G.; Patel, V.; Ku, N. C.; Pauff, J. M.; Eyre, T. A.; Jurczak, W.; Le Gouill, S. |
| Abstract Title: | A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress) |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413901154 |
| DOI: | 10.1182/blood-2021-145380 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2424 -- Hybrid meeting, also took place online -- Source: Wos |
